All good points. We’re down to the short strokes here, and the defendants are just about out of paths to success. I think there’s a good chance the upcoming ruling may push generics to settle, provided Reduce-It is allowed. But I do still think Amarin took a big chance knowingly withholding the R-I/ FDA docs. Hopefully the court will not come down too hard on them.